Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : WR, LB and Friends. NO HYPESTERS OR SCAMMERS -- Ignore unavailable to you. Want to Upgrade?

To: Wayne Rumball who wrote (6799)	4/9/1999 12:40:00 PM
From: J.R.S.	Respond to of 13776

WWWX has been launched!!!!

To: Wayne Rumball who wrote (6799)	4/9/1999 12:42:00 PM
From: last1out	Respond to of 13776

NGLD looks like it could be a good runner

To: Wayne Rumball who wrote (6799)	4/9/1999 1:20:00 PM
From: Due Diligence	Respond to of 13776

CRII news out. Financials. Warmest regards, DD quote.yahoo.com

To: Wayne Rumball who wrote (6799)	4/9/1999 1:46:00 PM
From: Frederick Langford	Read Replies (1) \| Respond to of 13776

Chosen as pick today from Undervalued Dog, looks like low risk (something new and different <gg> MIM Corporation (Nasdaq : MIMS) Industry: Healthcare Facilities Recent Price: $2.125 Daily Average Volume (3 Month Avg.): 80 K 52-Week Range: $2-$6.4375 Outstanding Shares: 17.8 million Active Float: 4.27 million Market Cap: $37.8 million 1998 Revenues: $451 million % Owned By Management and Insider: 60 % Owned by Institution: 16 (The Kaufman Mutual Fund, one of the best mutural funds, owns 5%) IPO by PaineWebber Inc.: $13 per share on 8/96 EPS: 0.29 PE: 7.23 1998 EPS: 0.29 Trailing PE: 7.33 Industry PE: 24.0 Book Value: $2.28 Price/Book: 0.93 Industry Price/Book: 2.56 Cash Flow (MRQ): 1.64 Beta: 2.59 Short Interest: 0.192 million Recommedation: Strong Buy Target Price or Takeover Price: $6-$7 within 3-12 months BUSINESS SUMMARY AND CORPORATION BACKGROUND: MIM Corporation (NASDAQ: MIMS) is an independent pharmacy benefit management and prescription mail service organization that partners with managed care organizations and healthcare providers to control prescription drug costs. MIM provides its customers with innovative pharmacy benefit products and services utilizing clinically sound guidelines to ensure cost control and quality care. MIM encourages improved quality of care, increased patient accessibility and medical cost effectiveness. Through its prescription mail service subsidiary, the Company provides mail order pharmacy distribution services with an emphasis on serving specific groups of individuals affected with diseases, particularly diabetes and AIDS, which require long-term maintenance medications. SUMMARY: There is a turnaround situation. In 1997, the company lost money at $1.07 per share. However, the company doubled its revenues, up to $451 million, in 1998 with earnings at 0.26 per share. Also we notice that the company has dramatically improved its gross and net profit margins in the past year. We believe the company will continue to do so this year. We estimate the earnings for 1999 will be $0.65 to $1.00 per share. We heard that the company may be able to report $0.25 per share for first quarter's earnings sometime next month. On April 5, 1999, MIMS announced the launch of Clinical Management System (CMS), a proprietary Internet-based claims reporting tool that provides customers in-depth drug utilization and financial information. Developed internally, CMS enables MIM's clinicians and customers to review claims transactions, perform cost analyses, generate customized reports, and trend cost information. CMS improves the communications between MIM and its customers through better understanding its physician prescribing habits and utilization trends. By keeping customers better informed with current data, more educated decisions can be made within a shorter time period, allowing for improved cost management. In addition, CMS' user-friendly graphic interface allows for easy operation of the application by executives from multiple disciplines within an organization. This development, we believe, will be another major step for the company to have another major revenue channel while the company is able to significantly reduce costs. The stock price was over $5 last December. Since then, the price has declined to the current level. Technical analysis suggests that there is a strong technical support in the range of $2 and the stock is extremely oversold. Bollinger Bands strongly tighten to the average, indicating that sharp moves of the price will occur. On Balance Volume has started to head in the opposite direction to the stock price, suggesting that direction of the price will be reversed. The stock has been basing for a while, as the stock gets little publicity in the investment community. We don't see much downside. With its solid fundamentals and earning potential, we believe the stock upside can easily reach $3 to $4 and then advance to $6 to $7 within next 3 months to 12 months! Also, the company is likely to be a takeover target. With appropriate valuation, the company should be worth about $6-$7. Contact: MIM Corporation Mr. Scott R. Yablon Phone: 914/460-1600 Fax: 914/460-1661

To: Wayne Rumball who wrote (6799)	4/9/1999 3:23:00 PM
From: Tom Allinder	Read Replies (3) \| Respond to of 13776

Just talked to Carey Whitehead at CULE... He says they are bringing on an individual who "is very well known and with outstanding marketing credentials." He couldn't tell me who. The news regarding this individual is going to be huge he says.... Also, the company is still negotiating with 3 PR firms. None of this means anything until it happens... There are many, long suffering CULE holders here. Including me. Tom